Literature DB >> 17344277

Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study.

Keith R Neal1, Sheena Ramsay, Brian J Thomson, William L Irving.   

Abstract

OBJECTIVE: We analysed the Trent Hepatitis C cohort to determine standardised mortality ratios in patients infected with hepatitis C virus (HCV), and to identify risk factors and associations with all-cause and liver-related mortality.
DESIGN: Cohort study.
SETTING: Patients with HCV infection attending secondary care within the Trent region of England. PATIENTS: 2285 patients with hepatitis C, followed for 1 year or more. MAIN OUTCOME MEASURES: The death rate in the cohort was compared to that seen in an age- and sex-matched English population. We performed Cox regression analyses to identify factors predictive of all-cause mortality and deaths from liver disease.
RESULTS: Standardised mortality ratios in the cohort were three times higher than those expected in the general population of England. The excess deaths were due to liver-related causes and those associated with a drug-using lifestyle. Significant independent predictors of all-cause mortality were age, sex, treatment (protective) and liver biopsy fibrosis. Age, treatment, liver biopsy fibrosis and mean alcohol consumption were predictors of liver-related mortality. HCV was mentioned on 23% of death certificates overall, and on 52% of those of patients dying from a liver-related cause.
CONCLUSIONS: Our findings demonstrate that the death rate in patients infected with hepatitis C is three times higher than expected. Severity of disease is associated with a worse prognosis, whilst treatment improves outcome, particularly in those who respond. Use of death certificate data on HCV infection for planning purposes will result in considerable under-estimation of the HCV-related disease burden.

Entities:  

Mesh:

Year:  2007        PMID: 17344277      PMCID: PMC1955506          DOI: 10.1136/gut.2006.113217

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  45-year follow-up of hepatitis C virus infection in healthy young adults.

Authors:  L B Seeff; R N Miller; C S Rabkin; Z Buskell-Bales; K D Straley-Eason; B L Smoak; L D Johnson; S R Lee; E L Kaplan
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

2.  The epidemiology of hepatitis C in a UK health regional population of 5.12 million.

Authors:  A H Mohsen
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 3.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

4.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

5.  Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study.

Authors:  L B Seeff; F B Hollinger; H J Alter; E C Wright; C M Cain; Z J Buskell; K G Ishak; F L Iber; D Toro; A Samanta; R L Koretz; R P Perrillo; Z D Goodman; R G Knodell; G Gitnick; T R Morgan; E R Schiff; S Lasky; C Stevens; R Z Vlahcevic; E Weinshel; T Tanwandee; H J Lin; L Barbosa
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  Progression of fibrosis in chronic hepatitis C.

Authors:  Marc G Ghany; David E Kleiner; Harvey Alter; Edward Doo; Farooq Khokar; Kittichai Promrat; David Herion; Yoon Park; T Jake Liang; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

7.  Laboratory surveillance of hepatitis C virus infection in England and Wales: 1992 to 1996.

Authors:  M E Ramsay; M A Balogun; M Collins; V Balraj
Journal:  Commun Dis Public Health       Date:  1998-06

8.  Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.

Authors:  S D Ryder; W L Irving; D A Jones; K R Neal; J C Underwood
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 9.  Viral hepatitis C.

Authors:  Thierry Poynard; Man-Fung Yuen; Vlad Ratziu; Ching Lung Lai
Journal:  Lancet       Date:  2003-12-20       Impact factor: 79.321

10.  Trends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin.

Authors:  Matthew Hickman; Peter Madden; John Henry; Allan Baker; Chris Wallace; Jon Wakefield; Gerry Stimson; Paul Elliott
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more
  16 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

Authors:  Adrian M Di Bisceglie; Anne M Stoddard; Jules L Dienstag; Mitchell L Shiffman; Leonard B Seeff; Herbert L Bonkovsky; Chihiro Morishima; Elizabeth C Wright; Kristin K Snow; William M Lee; Robert J Fontana; Timothy R Morgan; Marc G Ghany
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

3.  All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.

Authors:  Samer S El-Kamary; Ravi Jhaveri; Michelle D Shardell
Journal:  Clin Infect Dis       Date:  2011-06-10       Impact factor: 9.079

4.  Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics.

Authors:  Libang Yang; Kyle D Rudser; LeeAnn Higgins; Hugo R Rosen; Atif Zaman; Christopher L Corless; Larry David; Glenn R Gourley
Journal:  Dig Dis Sci       Date:  2011-05-17       Impact factor: 3.199

Review 5.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.

Authors:  Yamini Kalidindi; Jeah Jung; Roger Feldman; Thomas Riley
Journal:  JAMA Netw Open       Date:  2020-07-01

7.  Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study.

Authors:  Qing-Lei Zeng; Guo-Hua Feng; Ji-Yuan Zhang; Yan Chen; Bin Yang; Hui-Huang Huang; Xue-Xiu Zhang; Zheng Zhang; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study.

Authors:  Lars Haukali Omland; Peer Brehm Christensen; Henrik Krarup; Peter Jepsen; Nina Weis; Henrik Toft Sørensen; Niels Obel
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

9.  Current and future disease progression of the chronic HCV population in the United States.

Authors:  Martin Zalesak; Kevin Francis; Alex Gedeon; John Gillis; Kyle Hvidsten; Phyllis Kidder; Hong Li; Derek Martyn; Leslie Orne; Amanda Smith; Ann Kwong
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  Socioeconomic status in HCV infected patients - risk and prognosis.

Authors:  Lars Haukali Omland; Merete Osler; Peter Jepsen; Henrik Krarup; Nina Weis; Peer Brehm Christensen; Casper Roed; Henrik Toft Sørensen; Niels Obel
Journal:  Clin Epidemiol       Date:  2013-05-31       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.